Previous 10 | Next 10 |
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA ® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional ...
Amarin just launched its EPA drug Vazkepa in Europe. U.S. growth has stalled in the face of generic competition and loss of patent protection. While sales and cash on hand make the company look undervalued, the market won't reward them until real growth is realized. For furt...
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the first European launch of VAZKEPA (icosapent ethyl) in Germany. VAZKEPA received marketing authorization from the European Commission in March 2021 and the Medic...
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021. H. C. Wainwright 23 rd ...
The stock market is on a winning streak, with the benchmark S&P 500 index recording fresh highs for seven straight months. Given surging investor confidence and strong economic recovery, we think fundamentally sound low-priced stocks Wipro (WIT), Turkcell (TKC), Amarin (AMRN), and Loma Ne...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in ...
AMRN shares are up almost 30% last month, likely due in part to AMRN's success in keeping generics to 11% market share and the imminent European launch. AMRN share price is still near its lows since it reported its REDUCE-IT data in 2018. As the Nevada ANDA litigation ends as an A...
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction 2021 ESC Guidelines on Cardiovascular Disease Prevention now include VAZKEPA in their reco...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of my favorite InvestorPlace commentators is Josh Enomoto. He tells it like it is while providing a balanced analysis. For example, Enomoto recently discussed seven penny stocks getting lots of attention from the...
VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...